cancers-logo

Journal Browser

Journal Browser

Risk for Cancer-Associated Thrombosis

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: closed (15 September 2024) | Viewed by 1422

Special Issue Editor


E-Mail Website
Guest Editor
Általános Orvostudományi Kar, Debrecen, Hungary
Interests: transplantation; complications; acute leukemia myeloproliferative disorders; thrombocytopenia

Special Issue Information

Dear Colleagues,

Thrombotic complications remain the major sequelae (with respect to morbidity and mortality) of oncologic diseases due to their natural tumor course and treatment-related events, which are going to be discussed in this Special Issue of this journal.

Thrombotic complications may manifest as classical deep vein thrombosis/pulmonary embolism and visceral thrombosis, along with arterial thrombosis and chronic or sometimes acute disseminated intravascular coagulation. Thrombotic events are mainly linked to active cancer and even more with chemotherapy or hormonal and biological therapeutic modalities. Their pathomechanisms share many similarities (i.e., tissue factor activation, etc.), but there are also substantial differences (i.e., cereblons in myeloma, other mechanisms in some cerebral tumors, etc.) and complex issues using biological and different types of cell therapies.

Their treatment modalities are similar, mostly LMWH, increasingly DOAC based, rarely aspirin (e.g., myeloma cereblon-targeting agents), and involve approaches with a growing number of innovative therapeutic modalities.

The traditional approach of recommending protocols by tumor types is still in focus (considering the more or less thrombogenic type of cancers), but the time has come to summarize and conclude thrombogenicity/vascular issues and antithrombotic measures with other treatment trends (e.g., bone marrow transplantation, CAR+T cell interventions, angiogenesis modifiers, immunotherapies, etc.), which are going to be covered in separate chapters of this Special Issue.

Dr. Miklos Udvardy
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer and thrombosis
  • antithrombotic therapy
  • thrombotic and vascular events with transplantation and biological therapeutic modalities

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1764 KiB  
Article
Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies
by Jarosław Kępski, Sebastian Szmit and Ewa Lech-Marańda
Cancers 2024, 16(18), 3196; https://doi.org/10.3390/cancers16183196 - 19 Sep 2024
Cited by 1 | Viewed by 1108
Abstract
Objectives. Venous and arterial thromboembolism (VTE/ATE) often coexist with onco-hematologic diagnosis. This study aimed to assess the time relationship between the diagnosis of VTE/ATE and blood cancers. The second aim was to identify VTE/ATE risk factors related to the type of hematology disease [...] Read more.
Objectives. Venous and arterial thromboembolism (VTE/ATE) often coexist with onco-hematologic diagnosis. This study aimed to assess the time relationship between the diagnosis of VTE/ATE and blood cancers. The second aim was to identify VTE/ATE risk factors related to the type of hematology disease and cardiac history. Methods. A total of 1283 patients underwent cardio-oncology evaluation at the Institute of Hematology and Transfusion Medicine in Warsaw from March 2021 through March 2023 (2 years), and 101 (7.8%) cases were identified with VTE/ATE. Results. ATE compared with VTE significantly occurred more often before the diagnosis and treatment of hematologic malignancy: 33/47 (70.2%) vs. 15/54 (27.8%), p < 0.0001. The risk of a VTE episode is exceptionally high in the first months after the diagnosis of an onco-hematological disease and the initiation of anticancer treatment. The higher frequency of VTE was associated with acute myeloid leukemia (17 cases/270 patients/6.30%/p = 0.055), acute lymphocytic leukemia (7 cases/76 patients/9.21%/p = 0.025), and chronic myeloproliferative disease (7 cases/48 patients/14.58%/p = 0.0003). Only the risk of VTE was significantly increased before (OR = 6.79; 95% CI: 1.85–24.95; p = 0.004) and after diagnosis of myeloproliferative disease (OR = 3.12; 95% CI: 1.06–9.16; p = 0.04). Conclusions. ATEs occur more often than VTE before a diagnosis of blood cancer. The risk of VTE is exceptionally high before and after diagnosis of chronic myeloproliferative disease. Full article
(This article belongs to the Special Issue Risk for Cancer-Associated Thrombosis)
Show Figures

Figure 1

Back to TopTop